PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.23−0.13 (-0.22%)
Close on Nov 18, 2026Market cap $5.03BP/E –Yield –
PTC Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
PTC Therapeutics's operating income for the twelve months ending Sep 30, 2026 was $147.70M, down 81.0% year over year. For fiscal 2025 it was $866.94M. The highest annual figure on record is $866.94M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $866.94M | – |
| FY2024 | Dec 31, 2024 | -$302.57M | – |
| FY2023 | Dec 31, 2023 | -$439.50M | – |
| FY2022 | Dec 31, 2022 | -$447.41M | – |
| FY2021 | Dec 31, 2021 | -$374.44M | – |
| FY2020 | Dec 31, 2020 | -$431.77M | – |
| FY2019 | Dec 31, 2019 | -$241.16M | – |
| FY2018 | Dec 31, 2018 | -$115.69M | – |
| FY2017 | Dec 31, 2017 | -$64.29M | – |
| FY2016 | Dec 31, 2016 | -$132.06M | – |
| FY2015 | Dec 31, 2015 | -$167.13M | – |
| FY2014 | Dec 31, 2014 | -$99.41M | – |
| FY2013 | Dec 31, 2013 | -$45.40M | – |
| FY2012 | Dec 31, 2012 | -$26.81M | -187.7% |
| FY2011 | Dec 31, 2011 | $30.58M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $25.11M | +732.7% |
| Q2 FY2026 | Jun 30, 2026 | $148.98M | – |
| Q1 FY2026 | Mar 31, 2026 | $44.96M | -95.4% |
| Q4 FY2025 | Dec 31, 2025 | -$71.35M | – |
| Q3 FY2025 | Sep 30, 2025 | $3.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.96M | – |
| Q1 FY2025 | Mar 31, 2025 | $970.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$162.39M | -2890.2% |
| Q3 FY2024 | Sep 30, 2024 | -$54.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$45.45M | – |
| Q4 FY2023 | Dec 31, 2023 | $5.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$118.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$209.54M | – |
| Q1 FY2023 | Mar 31, 2023 | -$117.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$200.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$68.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$92.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$86.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$84.73M | – |
| Q3 FY2021 | Sep 30, 2021 | -$93.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$98.49M | – |
| Q1 FY2021 | Mar 31, 2021 | -$98.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$96.37M | – |
| Q3 FY2020 | Sep 30, 2020 | -$55.13M | – |
| Q2 FY2020 | Jun 30, 2020 | -$187.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$92.99M | – |
| Q4 FY2019 | Dec 31, 2019 | -$72.78M | – |
| Q3 FY2019 | Sep 30, 2019 | -$60.48M | – |
| Q2 FY2019 | Jun 30, 2019 | -$38.76M | – |
| Q1 FY2019 | Mar 31, 2019 | -$69.14M | – |
| Q4 FY2018 | Dec 31, 2018 | -$45.14M | -927.9% |
| Q3 FY2018 | Sep 30, 2018 | -$48.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.57M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.74M | – |
| Q4 FY2017 | Dec 31, 2017 | $5.45M | – |
| Q3 FY2017 | Sep 30, 2017 | -$30.89M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.50M | – |
| Q1 FY2017 | Mar 31, 2017 | -$26.36M | – |
| Q4 FY2016 | Dec 31, 2016 | -$24.99M | – |
See a number that looks wrong?